Dupilumab, marketed under the brand name Dupixent, is a monoclonal antibody used to treat several chronic inflammatory conditions. It works by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are cytokines involved in the inflammatory response. Dupilumab is approved for the treatment of several conditions, including, atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic esophagitis.